NCT06603558View on ClinicalTrials.gov

Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine

RecruitingOBSERVATIONAL
Enrollment

3,000

Participants

Timeline

Start Date

September 24, 2024

Primary Completion Date

May 31, 2029

Study Completion Date

May 31, 2029

Conditions
Chronic MigraineEpisodic MigraineMigraine
Interventions
DRUG

Atogepant

Oral Tablet

Trial Locations (4)

18450

RECRUITING

Hallym University Dongtan Sacred Heart Hospital /ID# 273581, Hwaseong

03080

RECRUITING

Seoul National University Hospital /ID# 271892, Seoul

03181

RECRUITING

Kangbuk Samsung Hospital /ID# 271893, Seoul

03722

RECRUITING

Yonsei University Health System Severance Hospital /ID# 272639, Seoul

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY